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Abstract
Background: Selenium (Se) status in non-deficient subjects is typically assessed by the Se contents of plasma/
serum. That pool comprises two functional, specific selenoprotein components and at least one non-functional,
non-specific components which respond differently to changes in Se intake. A more informative means of
characterizing Se status in non-deficient individuals is needed.
Methods: Multiple biomarkers of Se status (plasma Se, serum selenoprotein P [SEPP1], plasma glutathione
peroxidase activity [GPX3], buccal cell Se, urinary Se) were evaluated in relation to selenoprotein genotypes (GPX1,
GPX3, SEPP1, SEP15), dietary Se intake, and parameters of single-carbon metabolism in a cohort of healthy, non-Se-
deficient men (n = 106) and women (n = 155).
Conclusions: Plasma Se concentration was 142.0 ± 23.5 ng/ml, with GPX3 and serum-derived SEPP1 calculated to
comprise 20% and 34%, respectively, of that total. The balance, comprised of non-specific components, accounted
for virtually all of the interindividual variation in total plasma Se. Buccal cell Se was associated with age and plasma
homocysteine (hCys), but not plasma Se. SEPP1 showed a quadratic relationship with body mass index, peaking at
BMI 25-30. Urinary Se was greater in women than men, and was associated with metabolic body weight (kg
0.75),
plasma folate, vitamin B12 and hCys (negatively). One GPX1 genotype (679T/T) was associated with significantly
lower plasma Se levels than other allelic variants. Selenium intake, estimated from food frequency questionnaires,
did not predict Se status as indicated by any biomarker. These results show that genotype, methyl-group status
and BMI contribute to variation in Se biomarkers in Se-adequate individuals.
Background
That selenium (Se) plays roles in cancer prevention has
been demonstrated in numerous studies with a variety
of animal and cellular models [1-4] and in several clini-
cal trials [5-7]. Yet, the largest study, the Selenium and
Vitamin E Cancer Prevention Trial (SELECT), failed to
detect cancer risk reduction with Se-supplementation
[8], indicating that Se-supplementation may not benefit
all individuals.
Rayman et al [9] pointed out that the results of
SELECT are consistent with those of the Nutritional
Prevention of Cancer (NPC) Trial [7,10]. In NPC,
reduced prostate cancer risk was observed mostly
among subjects with baseline plasma Se concentrations
in the lowest tertile of the cohort, < 106 ng/ml [10]; no
risk reduction was noted for subjects with plasma Se >
123 ng/ml, concentrations comparable to those of the
subjects in SELECT, which averaged 136.5 ng/ml at
baseline [8]. Therefore, it is possible that Se-supplemen-
tation may yield anti-cancer benefits in individuals who
are below some threshold of Se status without being
deficient in the nutrient.
Assessment of Se status is difficult in individuals who
are not deficient, such as those of NPC and SELECT. It
is well established that Se-deficient individuals show
subnormal levels of several Se biomarkers, including
some with functional significance, such as the seleno-
proteins, and others that indicate the amounts of Se in
the body, such as the Se contents of tissues and body
fluids. Non-deficient individuals, however, have maximal
selenoenzyme expression [11-13], rendering those para-
meters non-informative regarding changes in Se intake.
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Plasma Se, while easily measured, is not a single
entity. It has several components, which, with our cur-
rent knowledge, are currently defined as: two selenopro-
teins (selenoprotein P [SEPP1] and the extracellular
GPX3), which specifically contain selenocysteine (SeCys)
[14,15]; Se incorporated non-specifically as SeMet in
lieu of methionine in albumin and other proteins
[16,17]; and a small amount of non-protein bound Se
[18,19]. These selenoproteins are fully expressed in Se-
adequate individuals; they comprised 22% (SEPP1) and
9% (GPX3) of plasma Se in an individual fed SeMet
[19]. In contrast, the non-specific incorporation of Se
into plasma proteins appears to be regulated only by
SeMet supply for which reason this component would
be expected to increase in response to supplementation
with SeMet [19], as in SELECT [7], or a source of
SeMet such as Se-yeast, as in NPC [8].
We determined multiple biomarkers of Se status in
the cohort of healthy Americans in order to elucidate
the relationships among those biomarkers and biologi-
cal, metabolic and genetic factors relevant to Se metabo-
lism. Herein we report the results of an extensive
assessment of Se status in that cohort.
Methods
Subjects
This study involved healthy men and women living in
vicinity of Grand Forks, ND, who volunteered and met
the following eligibility criteria: over 18 yrs., no chronic
liver or kidney diseases (based on blood chemistries and
urine analyses), nonsmokers, not having used
supplements providing > 50 ug Se/day in the past 6
months (to accommodate users of most OTC multivita-
min/mineral supplements), not currently using medica-
tions that adversely affect liver or kidney function, body
mass index (BMI) ≤ 40 kg/m
2. A total of 356 volunteers
were screened. Of 282 who met the eligibility criteria,
261 subjects (106 men, 155 women) were enrolled in the
study; selection and randomization of subjects is shown
in figure 1 and subject characteristics are indicated in
table 1. Each volunteer was given a cash honorarium pro-
rated for the duration of his/her participation in the
study.
Oversight was provided by the University of North
Dakota Human Subjects Committee which reviewed and
approved the protocol. The purposes and procedures of
the study were explained to the volunteers verbally and
in writing, and written informed consent was obtained
from each volunteer.
Anthropometry
Body weight was measured using an electronic scale.
Height was measured using a wall-mounted stadiometer.
Assessment of Dietary Intake
D i e t a r yi n t a k eo v e rt h et h r e ep r e v i o u sm o n t h sw a s
assessed by a single, self-administered food frequency
questionnaire (FFQ) patterned after the Harvard Service
Food Frequency Questionnaire format [20]. This FFQ
includes 78 food items without serving sizes indicated
(natural portion implied: e.g., one cup of milk, one slice
of bread). All food items on the FFQ were matched to
food codes from the USDA Nutrient Database for Stan-
dard Reference [21] or USDA Food and Nutrient
Figure 1 Selection and randomization of subjects.
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subjects designated their average consumption by mark-
ing one of nine frequency categories ranging from “zero
per month” to “six or more times per day”.T h ef r e -
quency chosen for each food item was converted to
daily intake, e.g., a response of “1-3 per month” was
converted to 0.07 servings per day (two servings per
m o n t h ) .T o t a le n e r g y ,p r o t e i n ,c a r b o h y d r a t ea n df a t
intake were calculated based on nutrient data for the
food codes matched to the FFQ food items. Selenium
intake cannot be calculated as selenium content of
foods varies widely, dependent on crop location. We
therefore utilized the Se core foods list developed by
Schubert et al [23] to provide suggested food intake pat-
terns. Foods were also sorted into groups using informa-
tion from the MyPyramid Equivalents Database for
USDA Survey Food Codes [24] as well as Friday and
Bowman [25].
Sample Collection and Preparation
Blood was collected by venipuncture in duplicate 7 ml
samples into heparinized, EDTA-treated and non-trea-
ted glass tubes. Aliquots of whole blood were subjected
to low-speed centrifugation to prepare erythrocyte, buffy
coat, plasma and serum fractions. Urine (24 hr samples)
was collected in sterile polycarbonate bottles. These spe-
cimens were held at 4°C pending the completion of
screening analyses; excess portions were held at -80°C.
Buccal cells were collected using a sterile toothbrush
according to Paetau, et al. [26]; cells were lysed in dis-
tilled water and lysates were held at -80°C for analysis.
Clinical Biochemical Analyses
Blood cells were counted using an automated system
(CellDyne 3500, Abbott Laboratories, Abbott Park, IL).
The activities of aspartate aminotransferase (E.C. 2.6.1.1)
and alanine aminotransferase (E.C. 2.6.1.2) were deter-
mined in serum using kits (AST2 and ALT2, respec-
t i v e l y ,J A SD i a g n o s t i c s ,I n c . ,M i a m i ,F L )a n da n
automated chemistry analyzer (Cobas Mira, Roche Diag-
nostic Systems, Inc., Sommerville, NJ). The same analy-
zer was used to determine blood urea nitrogen (BUN)
in serum, glucose and protein in plasma, and creatinine
in urine (#47381, #0458976160, #44903 and #47003,
respectively, Roche Diagnostic Systems, Inc., Sommer-
ville, NJ). Thyroid-stimulating hormone (TSH), non-pro-
tein bound thyroxine (T4) and triiodothyronine (T3)
were measured in serum using an automated, solid-
phase, two-site chemiluminescent immunometric assays
(LKTS1, LKF41 and LKF31, respectively, Immulite 1000
System, Diagnostic Products Corp., Los Angeles, CA).
Biomarkers of Se Status
Selenium status was assessed on the basis of the activity
of GPX and the amount of SEPP1 in serum, and the
amounts of Se in plasma, buccal cells and urine. The
activity of GPX3 (E.C. 1.11.1.9) was determined in
plasma by the method of Paglia and Valentine [27] as
modified by Lawrence and Burk [28]. Due to its affinity
for heparin, SEPP1 was measured in serum by an
enzyme-linked immunoassay [29]. Selenium was deter-
mined in plasma, buccal cells and urine by automated
electrothermal atomic absorption spectrophotometry
using a reduced palladium matrix modifier and an
instrument equipped with L’Vov platforms [7]. Certified
Standards were used (Alfa Aesar [Ward Hill, MA, USA],
Perkin Elmer [Waltham, MA, USA] and CPI [Santa
Rosa, CA, USA]) to prepare a calibration set daily with
each batch. Continuing calibration certification and a
continuing calibration blank were included at 10% fre-
quency and at the beginning and end of the daily batch.
An initial calibration verification from an alternate sup-
plier was validated the calibr a t i o ns e ta tt h eb e g i n n i n g
and end of each analytical series. Matrix effects for
plasma and urine were evaluated using quantitative
plasma and urine standards (NIST [Gaithersburg, MD,
USA], Seronorm [Billingstad, Norway] and Utak
[Munich, Germany]) to validate the percentage recovery
Table 1 Characteristics of the study cohort (N = 261
1)
characteristic value
Anthropometry
age, y 49.6 ± 16.3
2
BMI 27.4 ± 5.0
2
biomarkers of Se status
plasma Se, ng/mL 142.0 ± 23.5
2
plasma GPX3, nmoles NADPH/min/mg
protein
3.64 ± 0.54
2
serum SEPP1, μg/mL 3.43 (2.61, 4.51)
3
buccal cell Se, ng/mg protein 8.39 (5.59, 12.59)
3
urine Se, ng/mg creatinine 55.5 (40.8, 75.6)
3
other metabolic markers
serum folate, μg/mL 25.1 (13.2, 47.8)
3
serum vitamin B12, pg/mL 496 (313, 786)
3
serum homocysteine, μg/mL 6.8 (5.2, 8.9)
3
TSH, μIU/mL 2.35 (1.21, 4.56)
3
free T4, nmol/mL 1.35 ± 0.18
2
free T3, nmol/mL 2.91 ± 0.59
2
glucose, mg/dL 89.9 ± 13.1
2
dietary intakes
energy, kcals/d 2177 ± 721
2
protein, g/d 87.2 ± 29.4
2
fat, g/d carbohydrate (g/d) 84.9 ± 33.7
2 272.52 ± 104.1
2
Se, μg/d 109 ± 43
2
1 155 women, 106 men
2 mean ± S.D.
3 geometric mean (-1 S.D., +1 S.D.)
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commercially available quantitative standard for Se in
buccal cells, matrix effects of buccal cell preparations
were accounted for in the analysis by performing spike
recoveries using certified calibration standards added
directly to one of the samples.
Other Biochemical Analyses
Folic Acid, B12 and homocysteine (hCys) were measured
in serum by automated solid-phase, competitive chemi-
luminescent enzyme immunoassays (LKF01, LKVB1 and
LKH01, respectively, Immulite 1000 System, Diagnostic
Products Corp., Los Angeles, CA). Vitamin 8-Hydroxy-
2’-deoxyguanosine was measured in urine using a com-
petitive enzyme-linked immunosorbent assay (#21026,
Bioxytech, Oxis Health Products, Inc., Foster City, CA).
Genotyping
The genotypes of subjects were determined for genes for
several selenoenzymes (two glutathione peroxidases,
GPX1, GPX4; the transporter selenoprotein P, SEPP1;
and intracellular SEP15). Genomic DNA was extracted
from blood samples using a DNA isolation kit (Qiagen,
Valencia, CA). DNA was used as a template for PCR
amplification by modifications of previous reported pro-
cedures [30-33]. Negative controls were included. Unless
otherwise noted, PCR conditions were: 95°C - 3 min; 30
cycles at 95°C - 30 s; 55°C - 60 s; 72°C - 90 s; 72°C - 10
min. Amplified DNA was digested with the appropriate
restriction enzymes, and digestion products were sepa-
rated electrophoretically in 3% agarose unless otherwise
noted.
SEP15; rs5845 and rs5859
PCR primers [30] 5’-CAGACTTGCGGTTAATTATG-
3’and 5’-GCCAAGTATGTATCTGATCC-3’ were used
to generate a 413-bp amplification product of rs5845
and rs5859. Amplified DNA was digested with Dra I
restriction enzyme at position 811, or Bfa I restriction
enzyme at position 1125.
GPX4; rs713041
PCR primers [31] 5’-GACCTGCCCCACTATTTCTA-3’
and 5’-GTCTGTTTATTCCCACAAGG-3’ were used to
generate 221-bp amplification product of rs713041. PCR
conditions were as follows: 94°C - 2 m; 30 cycles at 94°
C - 30 s; 57.5°C - 30 s; 72°C - 1 min; 72°C - 7 m.
Amplified DNA was digested with restriction enzyme
StyI.
GPX1; rs1050450
PCR primers [32] 5’-TGTGCCCCTACGCAGGTA-3’
and 5’-CCAAATGACAATGACACAGG-3’ were used to
generate a 337-bp amplification product of rs1050450.
Amplified DNA was digested with the Apa I restriction
enzyme to identify C/T polymorphism at allele position
679, corresponding to amino acid position 198 of the
human GPX1 protein.
SEPP1; rs3877899
PCR primers [33] 5’-CACGCATTATTCCTATCTCTA-
TAAGCTTG-3’ and 5’-GGAAATGAAATTGTGTCTA-
GACTAAATTGG-3’ were used to generate a 722-bp
amplification product of rs3877899. To determine a G/
A variant at position 24731 in SEPP1 mRNA and a sec-
ond G/A variant (rs7579) at position 25191 of the refer-
ence mRNA sequence in the 3’UTR of mRNA, PCR
products were sent for sequencing (Cogenics, Newton,
MA) with sequencing primers 5’-CACGCATTATTC-
CTATCTCTATAAGCTTG-3’,5 ’-TCACCTGACA-
GTGTAAAGAAAACCTC-3’.
Statistical Analyses
All statistical analyses (Pearson and Spearman correla-
tions, regression analysis, ANOVA, non-parametric dis-
criminate analysis, Tukey contrast and orthogonal
contrast) were performed using SAS Version 9.1.3 (SAS
Institute, Inc., Cary NC). Data for buccal Se, urine Se,
SEPP1, folate, hCys and vitamin B12 were highly skewed
and were logarithmically transformed so that their dis-
tributions would more closely approximate a normal
distribution. For these variables, we report the geometric
mean with a 1 SD interval. All other data are expressed
as mean ± SD Pearson correlations and linear regres-
sions were computed between biomarkers of selenium
status and demographic variables, Se intake, and mea-
sured biochemical parameters. Because of the large
variability observed in the intakes of the food groups,
Spearman correlations were used to assess the relation-
ship between plasma Se and intakes of various food
groups. A discriminate analysis was performed to deter-
mine whether estimated Se Intake could predict the
r e l a t i v em a g n i t u d eo fp l a s m aS eu s i n gt h ef i r s ta n d
fourth quartiles of the latter. A nonparametric method
was used because the intake values were not normally
distributed. For the SEPP1 and BMI relationship, further
analysis was performed by use of both Tukey contrast
and orthogonal contrast to validate the correlation.
Results
Estimation of Dietary Selenium Intake
This cohort was of relatively high Se status, as indicated
by plasma Se level (142.0 ± 23.5 ng/ml) (figure 2) other
biomarkers of Se status (Table 1) and estimated daily Se
intake of 109.1 ± 43.6 μg/d. The major dietary sources
of Se were whole wheat bread/rolls, eggs, and spaghetti/
other pasta with sauce, which accounted for 21.8% of
estimated intake. The estimated Se intakes of men (122
±5 1μg/d) were highly significantly (p < 0.001) greater
than those of women (101 ± 35 μg/d). A core group of
Combs et al. Nutrition Journal 2011, 10:75
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consumed by this cohort; 9 of those foods provided half
of estimated daily Se intakes. The rankings of these
foods as sources of Se were similar for men and women.
Se Distribution in Blood
The major components of plasma Se were estimated
from the total plasma Se and the measured plasma
GPX3 activities and serum SEPP1 amounts using the
following assumptions; for the amount of SeCys, GPX3
enzyme rate constant of 2.8 × 10
4 nmol/min/mg, mole-
cular weight 92 kD, and (stoichiometry of 4 g-atoms Se
per mole as SeCYS [34]; for SEPP1 (glycosylated), aver-
age molecular weight 60 kD and stoichiometry of 9.9 g-
atoms Se per mole as SeCYS [35]. An assumption inher-
ent in the selection of this blood fraction for SEPP1 is
that insignificant amounts of SEPP1 protein are
removed during the clotting process. We employ this
common assumption, with the further caveat that
SEPP1 loss by clotting is assumed to be less than the
variance of SEPP1 found in the studied population
(Coefficient of Variation ~27%).
The difference between the total measured Se and the
amounts of Se corresponding to the activity of GPX3
and measured amount of SEPP1 was taken as the
amount of Se incorporated non-specifically into plasma
proteins, presumed to be predominately SeMet. By these
estimates, GPX3 and SEPP1 comprised approximately
20% and 34%, respectively of Se, while 47% of Se was
present as non-specific components (Table 2). Neither
the activity of GPX3, the amount of SEPP1 in serum,
nor the amounts of Se in buccal cells or urine were sig-
nificantly related to total plasma Se concentration. How-
ever, the non-specific component of plasma Se was
positively associated (r = 0.87, p < 0.0001) with plasma
Se (figure 3). SEPP1 concentration was associated with
plasma concentration of hCys, a marker of methylation
status (r = 0.13, P < 0.05) on an exponential basis.
Serum SEPP1, but not GPX3 activity or total plasma
Se, showed a significant quadratic relationship with
body mass index (BMI) (r
2 = 0.054, P < 0.002), being
lower in individuals at the low and high ends of the
BMI range (figure 4). In addition to the regression ana-
lysis shown in figure 4, ANOVA, Tukey contrast and
orthogonal contrast tests were performed. There were
only 2 subjects with BMI < 18; these were included in
the BMI < 25 group. The overall ANOVA was highly
significant, p = 0.0012. By Tukey contrast tests compar-
ing the means of the 3 groups, the mean of the lowest
BMI group was highly significantly less than the mean
of the overweight group, p = 0.0008. An orthogonal
contrast test showed a significant quadratic trend in the
means of the 3 groups, p = 0.003. The back-transformed
SEPP1 means (± 1 S.D.) are as follows: BMI < 25: 3.17
(3.07-3.26); BMI 25-30: 3.69 (3.59-3.80); BMI > 30: 3.46
(3.36-3.58). Figure 4 makes evident the presence of two
outlier subjects. With all values included in the quadra-
tic regression of SEPP1 vs BMI, R
2 = 0.054, p = 0.0016.
Excluding the two high values improved the fit slightly:
R
2 = 0.0596, p = 0.0009.
Determinants of Se Status
Plasma Se level was not significantly associated with Se
intake estimated by FFQ (figure 5); however, it was sig-
nificantly associated with numbers of servings of foods
in four food groups: fish (r = 0.14, P < 0.022), fish sub-
category “other” (including fish other than tuna; r =
0.15, P < 0.014); dairy (r = 0.13, P < 0.036), and cured
meat (including sausage and luncheon meats; r = 0.15, P
< 0.019). A discriminate analysis showed that food Se
i n t a k ec o r r e c t l yp r e d i c t e dt h ep l a s m aS eq u a r t i l ef o r
about 73% of the individuals. The foods selected by the
analysis are shown in Table 3. Plasma Se level was not
significantly different between men and women, or
between users and non-users of nutritional supplements.
We assumed that the maximum amount of Se con-
sumed from supplements (<50 ug/day) would fall within
Figure 2 Frequency distribution of baseline plasma Se levels.
Table 2 Components of blood Se
component amount of Se ng/ml % total
Plasma GPX3-SeCYS
1 27.9 ± 4.3
5 20.2 ± 5.1
5
Serum SEPP1-SeCYS
2 46.5 ± 13.7 33.5 ± 11.6
Total non-specific Se
3 68.5 ± 27.1 46.5 ± 14.0
total
4 142.6 ± 24.3 100%
1estimated from measured enzyme activity; see text for details.
2estimated from measured protein levels; see text for details.
3imputed; see text for details.
4determined by direct measurement
5mean ± S.D., n = 233
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intake. That assumption is borne out by our finding of
no significant differences in the plasma Se levels
between supplement users and non-users for plasma Se.
Plasma Se was not significantly associated with age,
metabolic body weight (kg
0.75), or serum concentration
of folate, vitamin B12 or hCys.
Buccal cell Se was not significantly different for men
vs. women; however, that of users of nutritional supple-
ments (9.22 [5.89, 14.45]
4 ng/mg protein, n = 81) was
significantly greater (p < 0.02) than that of non-users
(8.03 [5.50, 11.73]
4 ng/mg protein, n = 179). Buccal cell
Se was significantly associated with age (r = 0.14, P <
0.02) and with serum hCys (r = 0.24. P < 0.0001) on
exponential bases. It was not, however, associated with
BMI, metabolic body size, or serum concentrations of
folate or vitamin B12.
The urinary Se level of women (geometric mean [-1S.
D., +1 S.D.]; 57.7 [42.3, 78.6] ng/mg creatinine) was sig-
nificantly greater (p < 0.003) than that of men (51.8
[39.8, 67.5]
3 ng/mg creatinine); that of users of nutri-
tional supplements (geometric mean [-1S.D., +1 S.D.];
59.3 [44.0, 80.0] ng/mg creatinine, n = 80) was signifi-
cantly greater (p < 0.01) than that of non-users (53.5
[40.0, 71.5]
3 ng/mg creatinine, n = 180). Urinary Se was
not significantly associated with age or BMI; but it was
significantly associated with metabolic body weight
(kg
0.75) (r = -0.14, p < 0.024) and with serum levels of
folate (r = 0.17, P < 0.006) and vitamin B12 (r = 0.34, P
< 0.0001) and negatively with serum hCys (r = -0.16, P
< 0.009) on exponential bases.
This cohort showed heterogeneity with respect to the
genotypes for each of the selenoproteins determined,
three of which were significantly related to a biomarker
of Se status (Table 4). Individuals with the GPX1 679 T/
T genotype (rs1050450) constituted 11% of the cohort
and had significantly lower (by 7%) plasma Se levels
than those with the most prevalent (47%) GPX1 679 C/
Figure 4 Relationship of serum SEPP1 level and body mass
index (BMI).
Figure 5 Relationship of plasma Se level and estimated Se
dietary intake.
Figure 3 Relationships of plasma Se level and values of other
biomarkers of Se status. From top to bottom: Panel A. Plasma
GPX3; Panel B. Serum SEPP1 level; Panel C. Buccal cell Se level; Panel
D. Urinary Se level; Panel E. Plasma non-specific Se (as described in
the text).
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otype (rs3877899) constituted 44% of the cohort and
had significantly lower (by 11%) serum SEPP1 levels
than those with the SEPP1 25191 G/G genotype, which
constituted a similar portion of the cohort. Individuals
with the SEP15 811 T/C genotype (rs5845) constituted
31% of the cohort and had significantly lower (by 15%)
buccal cell Se levels than those with the most prevalent
(65%) SEP15 8 1 1C / Cg e n o t y p e .N oo t h e rd i f f e r e n c e s
were found in the values of Se biomarkers due to these
genotypes, or due to GPX4 genotype (rs713041).
Discussion
The available biomarkers of Se status have been devel-
oped for use in individuals suboptimally nourished with
respect to the element. Indeed, they have been found
generally useful in such cases, as differences in their
values tend to correlate with differences in Se intake.
More importantly, two of those biomarkers have direct
functional significance: GPX3 participates in antioxidant
function; while SEPP1 is involved in Se transport and
also has antioxidant properties. However, these biomar-
kers are not informative of Se status under conditions of
Se intake exceeding the level necessary to support their
maximal expression, which coincides with the level
apparently effective in reducing cancer risk.
This study demonstrates the problem of characterizing
the Se status of a cohort that is not deficient in the ele-
ment. It shows the discordance of biomarkers of Se sta-
tus in a cohort of healthy Americans and the lack of
utility of biomarkers with functional significance to
assess Se status in a Se-adequate population. The most
commonly used biomarker of Se status, plasma Se con-
tent, is presumed to reflect both the amounts of Se in
various body pools and the level of Se intake [19]. At
142.0 ± 23.5 ng/ml, it showed that this cohort was of
Table 3 Foods Selected as Predictive of Plasma Se
Foods Mean Se Intake (μg/day)
1
st Quartile: 4
th Quartile:
Fish, halibut, cooked, dry heat 1.87 ± 2.83 3.29 ± 4.06
Alcoholic beverage, beer, regular 0.93 ± 1.71 0.42 ± 0.81
Egg, whole, cooked, scrambled 9.67 ± 12.4 6.33 ± 6.02
Seeds, sunflower seed kernels, oil roasted, salt added 1.37 ± 2.31 3.79 ± 8.44
Nuts, mixed nuts, oil roasted, with peanuts, salt added 3.18 ± 4.84 2.16 ± 3.78
Pork, fresh, shoulder, blade, roasts, separable lean only, cooked, roasted 3.98 ± 3.73 3.11 ± 3.29
Table 4 Effects of selenoprotein genotype of biomarkers of Se status
1.
gene allele
position-base
function/protein
position
n plasma Se
ng/ml
GPX3 nmol/
min/mg
serum SEPP1
ng/ml
buccal cell Se ng/
mg prot
urine Se ng/mg
creatinine
GPX1 679 T/T Leu198Leu 28 135.7 ± 19.0
a 3.67 ± 0.40 3.34 (2.58, 4.33)
2 7.72 (5.10, 11.66)
2 55.84 (42.80, 72.85)
2
679 T/C Leu198Pro 113 139.5 ± 23.1
a,b 3.60 ± 0.53 3.60 (2.86, 4.54) 8.86 (5.89, 13.31) 56.69 (41.85, 76.78)
679 C/C Pro198Leu 119 145.9 ± 24.3
b 3.67 ± 0.58 3.30 (2.43, 4.49) 8.13 (5.44, 12.15) 53.74 (39.92, 72.35)
GPX4 718-C/C UTR-3 74 142.0 ± 23.2 3.63 ± 0.53 3.40 (2.65, 4.38) 8.25 (5.34, 12.73) 56.86 (42.31, 76.43)
718-C/T UTR-3 135 141.3 ± 22.8 3.66 ± 0.56 3.43 (2.55, 4.62) 8.53 (5.86, 12.41) 54.78 (41.71, 71.96)
718-T/T UTR-3 51 143.9 ± 25.9 3.61 ± 0.53 3.49 (2.75, 4.42) 8.24 (5.25, 12.95) 54.14 (37.88, 77.38)
SEPP1 24731-A/A Thr234Thr 11 129.7 ± 27.9 3.66 ± 0.49 4.07 (3.55, 4.66) 6.92 (4.64, 10.31) 59.01 (46.36, 75.12)
24731-G/A Thr234Ala 98 140.1 ± 23.0 3.57 ± 0.56 3.41 (2.55, 4.55) 8.41 (5.46, 12.95) 53.14 (40.52, 69.69)
24731-G/G Ala234Ala 151 144.2 ± 23.3 3.69 ± 0.53 3.41 (2.61, 4.45) 8.49 (5.75, 12.55) 56.38 (41.15, 77.23)
25191-A/A UTR-3 31 145.0 ± 28.4 3.76 ± 0.63 3.49 (2.91, 4.18)
ab 8.88 (5.70, 13.84) 55.17 (39.58, 76.90)
25191-G/A UTR-3 115 141.8 ± 21.6 3.63 ± 0.58 3.24 (2.44, 4.31)
a 8.55 (5.71, 12.81) 54.40 (39.95, 74.08)
25191-G/G UTR-3 114 141.5 ± 24.0 3.63 ± 0.47 3.62 (2.75, 4.76)
b 8.10 (5.42, 12.09) 56.10 (42.58, 73.92)
SEP15 811-C/C UTR-3 169 143.2 ± 24.4 3.63 ± 0.55 3.45 (2.72, 4.38) 8.77 (5.85, 13.14)
a 56.73 (41.87, 76.87)
811-T/C UTR-3 81 139.0 ± 21.6 3.67 ± 0.53 3.38 (2.40, 4.74) 7.65 (5.06, 11.57)
b 52.45 (39.32, 69.97)
811-T/T UTR-3 10 145.2 ± 23.1 3.56 ± 0.43 3.67 (3.10, 4.35) 8.27 (6.16, 11.10)
ab 53.61 (44.36, 64.80)
1 155 women, 106 men
2 geometric mean (-1SD, +1SD)
3 Values within a gene-biomarker group having the same lettered superscript were not significantly different (p > 0.05)
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Page 7 of 10relatively high Se status. Half of subjects had plasma Se
levels comparable to those of the upper quintile of the
NHANES 2003-2004 cohort [11], and 6% had plasma Se
levels in the range achieved only by Se-supplementation
in the NPC trial [7]. No subject had a plasma Se level
<70 ng/ml, above which Nève [12] noted subjects do
not show GPX3 responses to Se-supplementation.
Accordingly, plasma Se levels, all of which were above
that threshold, were not associated with differences in
GPX3 activity or SEPP1 level. This indicates maximal
expression of those selenoproteins, rendering their mea-
surement uninformative as biomarkers of Se status in
this cohort. Differences in SeMet intake affect only the
non-specific component of plasma Se, is also likely
applicable to other such populations of relatively high
Se status
Hill et al [13] estimated that GPX3 and SEPP1, when
maximally expressed, should account for about 80 ng/
ml of the Se in human plasma. Their estimate was
based on the amount of Se associated with SEPP1 in
one apparently Se-adequate individual, and the amount
of Se reported by Avissar et al [11] to be associated with
GPX3. The GPX3 activities and SEPP1 levels of our
cohort indicate a slightly lower value, approximately 73
ng/ml, which may reflect weaknesses in our assump-
tions, particularly those concerning SEPP1. From the
reports of Steinbrenner et al [36] and Méplan et al [37],
we assumed the presence of multiple SEPP1 variants
with an average molecular weight of 60 kD. We also
assumed that SEPP1 contained an average of 9.9 g-
atoms Se as SeCys per mole based on the findings of
Saito et al [35] with human SEPP1; although the genetic
coding of the protein would suggest the possibility of as
many as 10 SeCys residues per mole [38]. Our estimate
suggests that the amount of Se present as SeCys in
GPX3 and SEPP1 comprised about 54% of the total
amount of Se in the plasma of these non-deficient sub-
jects, a lower percentage than observed (80%) by Deagen
et al [39] for Se-deficient men in China. The differences
between these different cohorts may reflect the preferen-
tial response of the non-specific plasma pool to SeMet.
This phenomenon is indicated by nearly half (47%) of
plasma Se occurring in the non-specific fraction in the
present cohort. Indeed, the variation we observed in
plasma Se level was almost exclusively limited to varia-
tion in the non-specific component. That this non-spe-
cific fraction was not confounded by such variables such
as age, gender, metabolic body weight or methylation
status (serum folate, vitamin B12, Hcy) suggests that it
may be a useful biomarker of Se status in non-deficient
populations; since differences in SeMet intake affect
only the non-specific component of plasma Se, these
findings are also likely applicable to other such popula-
tions of relatively high Se status.
We are not aware of buccal cells, which offer the advan-
tage of sampling a metabolically active tissue, having been
used previously to assess somatic cell Se. We found buccal
cells to contain appreciable amounts of Se; however, their
Se showed no significant correlation with plasma Se level.
The levels of Se in buccal cells and urine were each posi-
tively associated with the use of nutritional supplements.
In this regard, these biomarkers may be more useful than
plasma Se, which did not show such an effect.
Urinary Se, which consists mostly of methylated sele-
nosugars [40-42], was the only Se biomarker not in
dynamic equilibrium with other pools of Se in the body,
although it would be expected to show first-order rela-
tionships with such pools. That urinary Se was also posi-
tively associated with serum folate and vitamin B12,b u t
negatively associated with serum hCys, is consistent with
its metabolic production being dependent on the avail-
ability of methyl groups. This is supported by the findings
of Gonzalez et al. [43] that serum Se level was positively
associated with serum folate level and negatively asso-
ciated with serum hCys level, the latter explaining nearly
6% of the variance of serum Se. The lack of a relationship
between plasma Se and urinary Se suggests that these
two pools are not in a first-order relationship. Because
t h en o n - s p e c i f i cS ew a st h eo n l yv a r i a b l ec o m p o n e n to f
plasma Se, it’s apparent that very little of that protein-
bound pool turns over into urine. The dimorphic Se
excretion between men and women adds to the list of
sex-specific differences in (hepatic) Se metabolism, which
has been observed in both rodents and humans [44].
The relationship of serum SEPP1 and BMI (r
2 = 0.054;
p < 0.001), with greatest values among subjects with
BMIs of 25-30 (figure 4), was unexpected as Kimmons et
al [45] noted low plasma Se levels (<100 ng/ml) some-
what more frequently among women in this BMI class in
the NHANES III cohort. That this may reflect the dysre-
gulation of gluconeogenesis in obesity is suggested by
studies in cultured cells that have shown SEPP1 to be
regulated as a gluconeogenic enzyme [46-48].
It is also clear that genetic variability contributes to
variance of Se biomarkers. Of the four allelic selenopro-
tein variants studied three, GPX1, SEPP1 and SEP15,
were significantly related to the values of a Se biomarker
(Table 4). That individuals with GPX1 679T/T alleles
showed significantly lower plasma Se levels than those
of the C/C alleles is of particular interest, as the former
genotype has been associated with increased risk to can-
cers of the lung [49] and breast [50]. That some SEPP1
genotypes have less (11%) SEPP1 expression than others,
and that low BMI individuals had significantly lower
SEPP1 than those with mid-level and high BMI, it is
possible that SEPP1 in some individuals in this cohort
may not be maximally expressed, even at these appar-
ently adequate levels of Se intake.
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Page 8 of 10The estimated intakes of macronutrients were similar
to those reported for other cohorts of Americans [24].
However, estimated Se intake did not significantly corre-
late with any Se-biomarker. This is not surprising, con-
sidering the inherent errors in determining nutrient
intakes from an FFQ and in estimating the amount of
Se in particular foods, which can vary considerably
depending on the location and/or means of food pro-
duction [51]. The results of the FFQ method suggested
that a core group of 22 foods provided 80% of the Se
consumed by this cohort, a number similar to that esti-
mated by Schubert et al [23] for the American popula-
tion. This core included pork, beef and wheat products,
the Se contents of which Finley et al [52,53] showed can
vary enormously (by 3-, 11- and 57-fold, respectively,
for items purchased in the upper Midwest). Such great
uncertainty severely compromises the value of Se intake
estimated in this way as a useful indicator of Se status.
Conclusions
The assessment of Se status in individuals that are not defi-
cient in Se calls for the use of non-classical/unconventional
parameters that may be informative despite their limited
direct functional significance. In a cohort of healthy Ameri-
cans, Se intake, estimated using accepted FFQ methodol-
ogy, was not associated with any biomarkers of Se status;
the high degree of uncertainty inherent in this approach
rendered it unsuitable for predicting Se status. Two widely
used Se biomarkers, GPX3 and SEPP1, showed little corre-
lation with one another. Each appeared to be maximally
expressed, neither being associated with total plasma Se. In
contrast, Se in the non-specific component of plasma was
positively associated with total plasma Se.
It is clear that plasma Se comprises the Se specifically
incorporated as SeCys in GPX3 and SEPP1, as well as
Se present as SeMet incorporated non-specifically into
the plasma proteins. One would also expect plasma also
to contain small amounts of Se-metabolites some of
which may be noncovalently associated with plasma
proteins. In this cohort the non-specific pool was the
dominant component, comprising 47% of plasma Se and
representing most of the variance in that biomaker. It
would therefore appear to be the most useful parameter
of Se status in such a cohort.
What we have called the non-specific component of
plasma Se was imputed from our measurements of
other biomarkers. In order to use it for assessing Se sta-
tus in non-deficient individuals, it will be necessary to
assess it directly. This will mean developing means to
assess its various components, which we would expect
to include mostly protein-bound SeMet, but also smaller
amounts of Se bound to protein-thiols and non-protein
bound Se-metabolites including selenosugars.
These results demonstrate that factors other than Se
intake that can contribute to variance in Se biomarkers
used to assess Se status. Such factors include genotype,
methyl-group status, and BMI. It is possible that these
factors may contribute to heterogeneity in biomarker
responses to Se-supplementation, a problem noted by
Ashton et al [54].
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